These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy. Carr A; Grund B; Schwartz AV; Avihingsanon A; Badal-Faesen S; Bernadino JI; Estrada V; La Rosa A; Mallon P; Pujari S; White D; Wyman Engen N; Ensrud K; Hoy JF; HIV Med; 2020 Jan; 21(1):64-70. PubMed ID: 31642586 [TBL] [Abstract][Full Text] [Related]
3. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. Yin MT; Shi Q; Hoover DR; Anastos K; Sharma A; Young M; Levine A; Cohen MH; Shane E; Golub ET; Tien PC AIDS; 2010 Nov; 24(17):2679-86. PubMed ID: 20859192 [TBL] [Abstract][Full Text] [Related]
6. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A; J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589 [TBL] [Abstract][Full Text] [Related]
7. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537 [TBL] [Abstract][Full Text] [Related]
8. Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Borges ÁH; Hoy J; Florence E; Sedlacek D; Stellbrink HJ; Uzdaviniene V; Tomazic J; Gargalianos-Kakolyris P; Schmid P; Orkin C; Pedersen C; Leen C; Pradier C; Mulcahy F; Ridolfo AL; Staub T; Maltez F; Weber R; Flamholc L; Kyselyova G; Lundgren JD; Mocroft A; Clin Infect Dis; 2017 May; 64(10):1413-1421. PubMed ID: 28329090 [TBL] [Abstract][Full Text] [Related]
9. Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Worodria W; Massinga-Loembe M; Mayanja-Kizza H; Namaganda J; Kambugu A; Manabe YC; Kestens L; Colebunders R Clin Dev Immunol; 2011; 2011():758350. PubMed ID: 21197091 [TBL] [Abstract][Full Text] [Related]
10. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Prior J; Burdge D; Maan E; Milner R; Hankins C; Klein M; Walmsley S Osteoporos Int; 2007 Oct; 18(10):1345-53. PubMed ID: 17665239 [TBL] [Abstract][Full Text] [Related]
11. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. Chao C; Leyden WA; Xu L; Horberg MA; Klein D; Towner WJ; Quesenberry CP; Abrams DI; Silverberg MJ AIDS; 2012 Nov; 26(17):2223-31. PubMed ID: 22951631 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. Kalayjian RC; Lau B; Mechekano RN; Crane HM; Rodriguez B; Salata RA; Krishnasami Z; Willig JH; Martin JN; Moore RD; Eron JJ; Kitahata MM AIDS; 2012 Sep; 26(15):1907-15. PubMed ID: 22824630 [TBL] [Abstract][Full Text] [Related]
13. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. Hermans SM; van Leth F; Manabe YC; Hoepelman AI; Lange JM; Kambugu A HIV Med; 2012 Jul; 13(6):337-44. PubMed ID: 22296211 [TBL] [Abstract][Full Text] [Related]
14. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA; Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971 [TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. Krishnan S; Schouten JT; Atkinson B; Brown T; Wohl D; McComsey GA; Glesby MJ; Shikuma C; Haubrich R; Tebas P; Campbell TB; Jacobson DL J Acquir Immune Defic Syndr; 2012 Nov; 61(3):381-9. PubMed ID: 22828718 [TBL] [Abstract][Full Text] [Related]
16. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark. Folkestad L Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932 [TBL] [Abstract][Full Text] [Related]
17. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl. Maman D; Pujades-Rodriguez M; Nicholas S; McGuire M; Szumilin E; Ecochard R; Etard JF AIDS; 2012 Jul; 26(11):1393-8. PubMed ID: 22441247 [TBL] [Abstract][Full Text] [Related]
18. [Antiretroviral treatment discontinuation and its influencing factors among HIV-infected patients who initiated ART from 2012 to 2015 in Wenshan prefecture, Yunnan Province]. Hu XS; Zhao Y; Huang LL; Luo YX; Wu ZY Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Nov; 51(11):982-987. PubMed ID: 29136742 [No Abstract] [Full Text] [Related]
19. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. Baker JV; Peng G; Rapkin J; Krason D; Reilly C; Cavert WP; Abrams DI; MacArthur RD; Henry K; Neaton JD; J Acquir Immune Defic Syndr; 2008 Aug; 48(5):541-6. PubMed ID: 18645520 [TBL] [Abstract][Full Text] [Related]